The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Organ–based / Targeted Drug Delivery Devices Market for Biologics (Intra-organ / Intra-tumoral), 2020 - 2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    July 2020

  • Pages
    283

  • View Count
    560

Example Insights

Targeted-Drug-Delivery-Devices-Market-for-Biologics-Context Targeted-Drug-Delivery-Devices-Market-for-Biologics-List-of-devices Targeted-Drug-Delivery-Devices-Market-for-Biologics-Distribution-by-type-of-Device
Targeted-Drug-Delivery-Devices-Market-for-Biologics-Promising-Therapeutic-Areas Targeted-Drug-Delivery-Devices-Market-for-Biologics-Clinical-Trial-Analysis Targeted-Drug-Delivery-Devices-Market-for-Biologics-Landscape
Targeted-Drug-Delivery-Devices-Market-for-Biologics-Market-forecast    

 

Overview

Over the years, advances in cell biology and pharmacology have led to the development of a variety of advanced biologics, which experts believe, possess the potential to address several unmet needs associated with the treatment of different types of diseases. Currently, there are more than 1,000 cell and gene therapies under development; most of which are being developed for the treatment of oncological disorders, cardiovascular disorders and neurological disorders. Additionally, over the last decade, multiple immunotherapies have been developed, and have led to a decrease in lung cancer and melanoma-related mortality. Despite their many benefits, biologics present a number of challenges, such as drug delivery related complexities, and immunogenicity concerns, which have been shown to result in systemic toxicity post therapy administration. To avoid such systemic toxic effects, a limited volume of drug is administered, which often results in a small amount of drug reaching the target organ. Further, from a pharmacological point of view, the drug stays at the target site for a limited time, hence decreasing the final therapeutic effect that can be achieved through prolonged and controlled drug delivery. Moreover, some of such treatment options, such as cell therapies, require periodic administration of additional therapy material, or complementary products, thereby, adding to the already complex invasive dosing procedure.   

In order to address some of the abovementioned challenges, a number of innovator companies in the biopharmaceutical sector are actively engaged in identifying targeted and effective delivery strategies for biologics, including gene therapies, cell / stem cell therapies, immunotherapies and therapeutic proteins. Examples of devices designed for the targeted delivery of biologics include (in alphabetic order, no selection criteria) Advance® CS, ExtroducerTM microcatheter, HelixTM biotherapeutic delivery system, ImmunoPulse® IL-12, SmartFlow® neuro ventricular cannula and MailPan®. Some of the aforementioned drug delivery devices have been demonstrated to have an improved therapeutic safety index, and are capable of accurately delivering biological interventions to the target physiological site. Further, certain implantable delivery systems have also been developed in order to prolong the therapeutic effect of biologics. Given the rapid pace of growth within the biopharmaceutical market, the demand for effective delivery systems is anticipated to increase in the foreseen future. This may be expected to create lucrative opportunities for stakeholders in the targeted drug delivery systems market.

Scope Of the Report

The ‘Organ-based / Targeted Drug Delivery Devices Market for Biologics (Intra-organ / Intra-tumoral), 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such medical devices, over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes: 

  • A detailed assessment of the companies involved in the development of targeted delivery devices for biologics, providing information and analyses based on a number of relevant parameters, such as type of device (encapsulated device, catheter, implant, electroporation delivery system, balloon, cannula and microrobot), status of development (approved, clinical and preclinical), target organ (brain, heart, abdomen, breast, eye, and others), target indication (Parkinson's disease, heart failure, diabetes, breast cancer, myocardial infarction, Alzheimer’s, solid tumors (specific type unknown), and others), target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), type of biologic delivered (cells, proteins, antibodies, enzymes, plasmids, growth factors, small peptides, neurotransmitters and modified RNA), type of therapy delivered (gene therapy, stem cell therapy, cell therapy, immunotherapy and RNA therapeutics) and route of administration (intra-tumoral, implantable, intraocular, intraputamen, intra-abdominal, intracardiac and others). In addition, the chapter includes information on the device developers, including details on type of stakeholder (industry and non-industry), year of establishment, company size (only for industry players) and location of headquarters.    
  • Elaborate profiles of devices that are currently approved or being evaluated in later stages of clinical development (phase III and above), featuring an overview of the device, its mechanism of action, current development status and key clinical trial results.
  • An assessment of the research activity in the neurological and cardiovascular disorders domain, in terms of the development of stem cell and gene therapies for the treatment these disorders. The chapter provides information and analysis on the recent publications and grants that are focused on the stem cell and gene therapies being developed for these therapeutic areas.
  • A clinical trial analysis of completed, ongoing and planned studies of various stem cell and gene therapies, based on various parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, type of therapy, therapeutic area, target indication, route of administration, key players, geographical location and enrolled patient population.
  • An analysis presenting the potential strategic partners (primarily stem cell and gene therapy developers) for targeted drug delivery device developers, based on different parameters, such as pipeline strength, target therapeutic area(s) and location of the headquarters of the company. 

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market, for the time period 2020-2030. Our year-wise projections for the current and future opportunity have further been segmented on the basis of [A] type of device (encapsulated device, catheter, electroporation delivery system, and cannula), [B] target organ (brain, heart, breast, eye, skin and pancreas), [C] target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), [D] target indication (Parkinson's disease, heart failure, breast cancer, melanoma, glioblastoma, myocardial ischemia, geographic atrophy, glaucoma, macular telangectasia, retinitis pigmentosa, non-infectious uveitis and mucopolysaccharidosis type III A) and [E] key geographical regions (North America, Europe and Asia-Pacific). To account for the uncertainties associated with the development of the devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Dr William L Rust, Founder and Chief Executive Officer, Seraxis
  • Manuel Pires, Junior Business Developer, Defymed
  • R. Lyle Hood, Assistant Professor, University of Texas at San Antonio
  • Anonymous, Postdoctoral Associate, Massachusetts Institute of Technology  

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What type of devices are capable of providing targeted delivery of biologics?
  • Who are the leading device developers in this domain?
  • What are the key promising therapeutic areas for the development of targeted drug delivery devices for stem cell and gene therapies?
  • Which companies can be considered as potential strategic partners for device developers?
  • How is the current and future opportunity likely to be distributed across key market segments and geographical regions?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the medical devices that are capable of targeted delivery of biologics market in the mid to long-term.

Chapter 3 provides a general overview of drug delivery devices for biologics, focusing on the different routes of administration and the challenges associated with these delivery devices. The chapter also highlights the need for the development of targeted delivery devices for biologics. In addition, it presents the information on the different types of these targeted devices, the key advantages offered and a section on concluding remarks.

Chapter 4 provides a detailed assessment of the companies involved in the development of targeted delivery devices for biologics, providing information and analyses based on a number of relevant parameters, such as type of device (encapsulated device, catheter, implant, electroporation delivery system, balloon, cannula and microrobot), status of development (approved, clinical and preclinical), target organ (brain, heart, abdomen, breast, eye, and others), target indication (Parkinson's disease, heart failure, diabetes, breast cancer, myocardial infarction, Alzheimer’s, solid tumors (specific type unknown), and others), target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), type of biologic delivered (cells, proteins, antibodies, enzymes, plasmids, growth factors, small peptides, neurotransmitters and modified RNA), type of therapy delivered (gene therapy, stem cell therapy, cell therapy, immunotherapy and RNA therapeutics) and route of administration (intra-tumoral, implantable, intraocular, intraputamen, intra-abdominal, intracardiac and others). In addition, the chapter includes information on the device developers, including details on type of stakeholder (industry and non-industry), year of establishment, company size (only for industry players) and location of headquarters.

Chapter 5 features elaborate profiles of devices that are currently approved or being evaluated in later stages of clinical development (phase III and above), featuring an overview of the device, its mechanism of action, current development status and key clinical trial results.

Chapter 6 features an elaborate assessment of the research activity in the neurological and cardiovascular disorders domain, in terms of the development of stem cell and gene therapies for the treatment these disorders. The chapter provides information and analysis on the recent publications and grants that are focused on the stem cell and gene therapies being developed for these therapeutic areas, since 2015.

Chapter 7 features a geographical clinical trial analysis of completed, ongoing and planned studies of various stem cell and gene therapies, based on various parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, type of therapy, therapeutic area, target indication, route of administration, key players, geographical location and enrolled patient population.

Chapter 8 features an analysis presenting the potential strategic partners (primarily stem cell and gene therapy developers) for targeted drug delivery device developers, based on different parameters, such as pipeline strength, target therapeutic area(s) and location of the headquarters of the company.
 
Chapter 9 presents a comprehensive market forecast analysis, highlighting the likely growth of the targeted drug delivery devices market for biologics, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] type of device (encapsulated device, catheter, electroporation delivery system, and cannula), [B] target organ (brain, heart, breast, eye, skin and pancreas), [C] target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), [D] target indication (Parkinson's disease, heart failure, breast cancer, melanoma, glioblastoma, myocardial ischemia, geographic atrophy, glaucoma, macular telangectasia, retinitis pigmentosa, non-infectious uveitis and mucopolysaccharidosis type III A) and [E] key geographical regions (North America, Europe and Asia-Pacific). To account for the uncertainties associated with the development of the devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  

Chapter 10 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 11 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in this domain. In this study, we spoke to William L Rust (Founder and Chief Executive Officer, Seraxis),  Manuel Pires (Junior Business Developer, Defymed),  R. Lyle Hood (Assistant Professor, University of Texas at San Antonio) and Anonymous (Postdoctoral Associate, Massachusetts Institute of Technology)

Chapter 12 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE

1.1. Scope of the Report 
1.2. Research Methodology 
1.3. Key Questions Answered
1.4 Chapter Outlines 

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Drug Delivery Devices for Biologics
3.3. Routes of Drug Administration
3.4. Challenges Associated with Drug Delivery
3.5. Need for Targeted Drug Delivery

3.6. Devices for Targeted Delivery of Biologics
3.6.1. Types of Devices
3.6.2. Key Advantages

3.7. Concluding Remarks

4. MARKET LANDSCAPE

4.1. Chapter Overview

4.2. Targeted Drug Delivery Devices for Biologics: Overall Market Landscape
4.2.1. Analysis by Type of Device
4.2.2. Analysis by Status of Development
4.2.3. Analysis by Target Organ
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Target Therapeutic Area
4.2.6. Analysis by Type of Biologic Delivered
4.2.7. Analysis by Type of Therapy Delivered
4.2.8. Analysis by Route of Administration

4.3. Targeted Drug Delivery Devices for Biologics: Additional Information

4.4. Targeted Drug Delivery Devices for Biologics: List of Developers
4.4.1. Analysis by Type of Stakeholder
4.4.2. Analysis by Year of Establishment
4.4.3. Analysis by Company Size
4.4.4. Analysis by Location of Headquarters

5. DEVICE PROFILES

5.1. Chapter Overview
5.2. Alcyone MEMS Cannula (AMCTM)
5.2.1. Device Overview
5.2.2. Development Status
5.2.3. Key Clinical Trial Results

5.3. Bullfrog® Micro-Infusion Device
5.3.1. Device Overview
5.3.2. Development Status
5.3.3. Key Clinical Trial Results

5.4. HelixTM Biotherapeutic Delivery System
5.4.1. Device Overview
5.4.2. Development Status
5.4.3. Key Clinical Trial Results

5.5. Orbit Subretinal Delivery System
5.5.1. Device Overview
5.5.2. Development Status
5.5.3. Key Clinical Trial Results

5.6. SmartFlow® Neuro Ventricular Cannula
5.6.1. Device Overview
5.6.2. Development Status
5.6.3. Key Clinical Trial Results

5.7. Renexus®
5.7.1. Device Overview
5.7.2. Development Status
5.7.3. Key Clinical Trial Results

6. PROMISING THERAPEUTIC AREAS

6.1. Chapter Overview
6.2. Neurological Disorders
6.2.1. Stem Cell Therapies
6.2.1.1. Publication Analysis
6.2.1.1.1. Methodology
6.2.1.1.2. List of Publications
6.2.1.1.3. Analysis by Number of Publications

6.2.1.2. Grant Analysis
6.2.1.2.1. Methodology
6.2.1.2.2. List of Academic Grants
6.2.1.2.3. Analysis by Number of Grants
6.2.1.2.4. Analysis by Grant Amount

6.2.2. Gene Therapies
6.2.2.1. Publication Analysis
6.2.2.1.1. Methodology
6.2.2.1.2. List of Publications
6.2.2.1.3. Analysis by Number of Publications

6.2.2.2. Grant Analysis
6.2.2.2.1. Methodology
6.2.2.2.2. List of Academic Grants
6.2.2.2.3. Analysis by Number of Grants
6.2.2.2.4. Analysis by Grant Amount

6.3. Cardiovascular Disorders
6.3.1. Stem Cell Therapies
6.3.1.1. Publication Analysis
6.3.1.1.1. Methodology
6.3.1.1.2. List of Publications
6.3.1.1.3. Analysis by Number of Publications

6.3.1.2. Grant Analysis
6.3.1.2.1. Methodology
6.3.1.2.2. List of Academic Grants
6.3.1.2.3. Analysis by Number of Grants
6.3.1.2.4. Analysis by Grant Amount

6.3.2. Gene Therapies
6.3.2.1. Publication Analysis
6.3.2.1.1. Methodology
6.3.2.1.2. List of Publications
6.3.2.1.3. Analysis by Number of Publications

6.3.2.2. Grant Analysis
6.3.2.2.1. Methodology
6.3.2.2.2. List of Academic Grants
6.3.2.2.3. Analysis by Number of Grants
6.3.2.2.4. Analysis by Grant Amount

6.3. Summary of R&D Activity

7. CLINICAL TRIAL ANALYSIS

7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Stem Cell and Gene Therapies: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Status
7.3.4. Analysis by Type of Sponsor / Collaborator 
7.3.5. Analysis by Type of Therapy 
7.3.6. Analysis by Therapeutic Area
7.3.7. Analysis by Therapeutic Indication 
7.3.8. Analysis by Route of Administration
7.3.9. Analysis by Trial Status and Trial Phase
7.3.10. Most Active Industry Players: Analysis by Number of Registered Stem Cell and Gene Therapy Clinical Trials
7.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Stem Cell and Gene Therapy Clinical Trials
7.3.12. Analysis by Geographical Location
7.3.13. Analysis by Geographical Location and Trial Phase
7.3.14. Analysis by Geographical Location and Trial Status
7.3.15. Analysis by Geographical Location and Therapeutic Area
7.3.16. Analysis by Patients Enrolled and Trial Registration Year
7.3.17. Analysis by Patients Enrolled and Trial Phase
7.3.18. Analysis by Patients Enrolled and Type of Therapy
7.3.19. Analysis by Patients Enrolled and Therapeutic Area
7.3.20. Analysis by Patients Enrolled, Trial Status and Geographical Location

7.4. Stem Cell Therapies: Clinical Trial Analysis 
7.4.1. Analysis by Trial Registration Year
7.4.2. Analysis by Trial Phase
7.4.3. Analysis by Trial Status
7.4.4. Analysis by Type of Sponsor / Collaborator 
7.4.5. Analysis by Therapeutic Area
7.4.6. Analysis by Therapeutic Indication
7.4.7. Analysis by Route of Administration
7.4.8. Analysis by Trial Status and Trial Phase
7.4.9. Analysis by Geographical Location
7.4.10. Analysis by Geographical Location and Trial Phase
7.4.11. Analysis by Geographical Location and Trial Status
7.4.12. Analysis by Geographical Location and Therapeutic Area
7.4.13. Analysis by Patients Enrolled and Trial Registration Year
7.4.14. Analysis by Patients Enrolled and Trial Phase
7.4.15. Analysis by Patients Enrolled and Therapeutic Area
7.4.16. Analysis by Patients Enrolled, Trial Status and Geographical Location

7.5. Gene Therapies: Clinical Trial Analysis 
7.5.1. Analysis by Trial Registration Year
7.5.2. Analysis by Trial Phase
7.5.3. Analysis by Trial Status
7.5.4. Analysis by Type of Sponsor / Collaborator 
7.5.5. Analysis by Therapeutic Area
7.5.6. Analysis by Therapeutic Indication
7.5.7. Analysis by Route of Administration
7.5.8. Analysis by Trial Status and Trial Phase 
7.5.9. Analysis by Geographical Location
7.5.10. Analysis by Geographical Location and Trial Phase
7.5.11. Analysis by Geographical Location and Trial Status
7.5.12. Analysis by Geographical Location and Therapeutic Area
7.5.13. Analysis by Patients Enrolled and Trial Registration Year
7.5.14. Analysis by Patients Enrolled and Trial Phase
7.5.15. Analysis by Patients Enrolled and Therapeutic Area
7.5.16. Analysis by Patients Enrolled, Trial Status and Geographical Location

8. LIKELY PARTNER ANALYSIS

8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Stem Cell Therapy Developers: Likely Partners for Device Developers
8.3.1. Opportunities in North America
8.3.1.1. Most Likely Partners 
8.3.1.2. Likely Partners
8.3.1.3. Less Likely Partners 

8.3.2. Opportunities in Europe
8.3.2.1. Most Likely Partners 
8.3.2.2. Likely Partners 
8.3.2.3. Less Likely Partners

8.3.3. Opportunities in Asia-Pacific and Rest of the World
8.3.3.1. Most Likely Partners
8.3.3.2. Likely Partners 
8.3.3.3. Less Likely Partners

8.4. Gene Therapy Developers: Likely Partner for Device Developers
8.4.1. Opportunities in North America
8.4.1.1. Most Likely Partners 
8.4.1.2. Likely Partners
8.4.1.3. Less Likely Partners 

8.4.2. Opportunities in Europe
8.4.2.1. Most Likely Partners 
8.4.2.2. Likely Partners 
8.4.2.3. Less Likely Partners

8.4.3. Opportunities in Asia-Pacific and Rest of the World
8.4.3.1. Most Likely Partners
8.4.3.2. Likely Partners 
8.4.3.3. Less Likely Partners

9. MARKET FORECAST

9.1. Chapter Overview
9.2. Forecast Methodology and Assumptions
9.3. Targeted Drug Delivery Devices Market for Biologics, 2022-2030
9.3.1. Targeted Drug Delivery Devices Market for Biologics: Distribution by Type of Device, 2022-2030
9.3.2. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Organ, 2022-2030
9.3.3. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Indication, 2022-2030
9.3.4. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Therapeutic Area, 2022-2030
9.3.5. Targeted Drug Delivery Devices Market for Biologics: Distribution by Key Geographical Regions, 2022-2030
9.3.5.1. Targeted Drug Delivery Devices Market for Biologics in North America, 2022-2030
9.3.5.2. Targeted Drug Delivery Devices Market for Biologics in Europe, 2022-2030
9.3.5.3. Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific Region, 2022-2030

10. CONCLUDING REMARKS

10.1. Chapter Overview
10.2. Key Takeaways

11. EXECUTIVE INSIGHTS

11.1. Chapter Overview
11.2. Seraxis
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Dr William L Rust, Founder and Chief Executive Officer

11.3. Defymed
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Manuel Pires, Junior Business Developer

11.4. University of Texas at San Antonio
11.4.1. Organization Snapshot
11.4.2. Interview Transcript: R. Lyle Hood, Assistant Professor

11.5. Massachusetts Institute of Technology
11.5.1. Organization Snapshot
11.5.2. Interview Transcript: Anonymous, Postdoctoral Associate

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Drug Delivery Devices for Biologics
Figure 3.2 Routes of Drug Administration
Figure 4.1 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device
Figure 4.2 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development
Figure 4.3 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Status of Development
Figure 4.4 Targeted Drug Delivery Devices for Biologics: Distribution by Target Organ
Figure 4.5 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Target Organ
Figure 4.6 Targeted Drug Delivery Devices for Biologics: Distribution by Target Indication
Figure 4.7 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area
Figure 4.8 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area and Status of Development
Figure 4.9 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Biologic Delivered
Figure 4.10 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Therapy Delivered
Figure 4.11 Targeted Drug Delivery Devices for Biologics: Distribution by Route of Administration
Figure 4.12 Targeted Drug Delivery Device Developers: Distribution by Type of Stakeholder
Figure 4.13 Targeted Drug Delivery Device Developers: Distribution by Year of Establishment
Figure 4.14 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Company Size
Figure 4.15 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Location of Headquarters
Figure 4.16 Targeted Drug Delivery Device Developers (Non-Industry Players): Distribution by Location of Headquarters
Figure 6.1 Stem Cell Therapies for Neurological Disorders, Publication Analysis: Cumulative Trend by Year, 2015-2020
Figure 6.2 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.3 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.4 Gene Therapies for Neurological Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Figure 6.5 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.6 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.7 Stem Cell Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Figure 6.8 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.9 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.10 Gene Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Figure 6.11 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.12 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.13 Summary of R&D Activity
Figure 7.1 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.3 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status
Figure 7.4 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 7.5 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Therapy
Figure 7.6 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.7 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Indication
Figure 7.8 Stem Cell and Gene Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.9 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.10 Most Active Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Figure 7.11 Stem Cell and Gene Therapy: Most Active Non-Industry Players by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Figure 7.12 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.13 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.14 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.15 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.16 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.17 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.18 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.19 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.20 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.21 Stem Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.22 Stem Cell Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.23 Stem Cell Therapy Clinical Trials: Distribution by Trial Status
Figure 7.24 Stem Cell Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 7.25 Stem Cell Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.26 Stem Cell Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.27 Stem Cell Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.28 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.29 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.30 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.31 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.32 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.33 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.34 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.35 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.36 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.37 Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.38 Gene Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.39 Gene Therapy Clinical Trials: Distribution by Trial Status
Figure 7.40 Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 7.41 Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.42 Gene Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.43 Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.44 Gene Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.45 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.46 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.47 Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.48 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.49 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.50 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.51 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.52 Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 8.1 Likely Partner Analysis: Distribution of Stem Cell Therapy Developers by Geography
Figure 8.2 Likely Partner Analysis: Distribution of Gene Therapy Developers by Geography
Figure 9.1. Targeted Drug Delivery Devices Market for Biologics, 2022-2030 (USD Million)
Figure 9.2. Targeted Drug Delivery Devices Market for Biologics, 2022-2030: Distribution by Type of Device (USD Million)
Figure 9.3. Targeted Drug Delivery Devices Market for Biologics, 2022-2030: Distribution by Target Organ (USD Million)
Figure 9.4. Targeted Drug Delivery Devices Market for Biologics, 2022-2030: Distribution by Target Indication (USD Million)
Figure 9.5. Targeted Drug Delivery Devices Market for Biologics, 2022-2030: Distribution by Target Therapeutic Area (USD Million)
Figure 9.6. Targeted Drug Delivery Devices Market for Biologics, 2022-2030: Distribution by Key Geographical Regions (USD Million)
Figure 9.7. Targeted Drug Delivery Devices Market for Biologics in North America, 2022-2030 (USD Million)
Figure 9.8. Targeted Drug Delivery Devices Market for Biologics in Europe, 2022-2030 (USD Million)
Figure 9.9. Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific, 2022-2030 (USD Million)

List Of Tables

Table 4.1 Targeted Drug Delivery Devices for Biologics: List of Approved / Under Development Devices
Table 4.2 Targeted Drug Delivery Devices for Biologics: Information on Type of Biologic Delivered, Type of Therapy Delivered and Route of Administration
Table 4.3 Targeted Drug Delivery Devices for Biologics: Additional Information
Table 4.4 Targeted Drug Delivery Devices for Biologics: List of Developers
Table 5.1 Targeted Drug Delivery Devices for Biologics: List of Devices Profiled
Table 5.2 Alcyone MEMS Cannula (AMCTM): List / Details of Clinical Trials
Table 5.3 Bullfrog® Micro-Infusion Device: List / Details of Clinical Trials
Table 5.4 HelixTM Biotherapeutic Delivery System: List / Details of Clinical Trials
Table 5.5 Orbit Subretinal Delivery System: List / Details of Clinical Trials
Table 5.6 SmartFlow® Neuro Ventricular Cannula: List / Details of Clinical Trials
Table 5.7 Renexus®: List / Details of Clinical Trials
Table 6.1 Stem Cell Therapies for Neurological Disorders: List of Approved / Under Development Therapies
Table 6.2 Stem Cell Therapies for Neurological Disorders: List of Publications, 2015-2020
Table 6.3 Stem Cell Therapies for Neurological Disorders: List of Academic Grants, 2015-2020
Table 6.4 Gene Therapies for Neurological Disorders: List of Approved / Under Development Therapies
Table 6.5 Gene Therapies for Neurological Disorders: List of Publications, 2015-2020
Table 6.6 Gene Therapies for Neurological Disorders: List of Academic Grants, 2015-2020
Table 6.7 Stem Cell Therapies for Cardiovascular Disorders: List of Approved / Under Development Therapies
Table 6.8 Stem Cell Therapies for Cardiovascular Disorders: List of Publications, 2015-2020
Table 6.9 Stem Cell Therapies for Cardiovascular Disorders: List of Academic Grants, 2015-2020
Table 6.10 Gene Therapies for Cardiovascular Disorders: List of Approved / Under Development Therapies
Table 6.11 Gene Therapies for Cardiovascular Disorders: List of Publications, 2015-2020
Table 6.12 Gene Therapies for Cardiovascular Disorders: List of Academic Grants, 2015-2020
Table 8.1 Opportunities in North America: Most Likely Stem Cell Therapy Partners for Device Developers
Table 8.2 Opportunities in North America: Likely Stem Cell Therapy Partners for Device Developers
Table 8.3 Opportunities in North America: Less Likely Stem Cell Therapy Partners for Device Developers
Table 8.4 Opportunities in Europe: Most Likely Stem Cell Therapy Partners for Device Developers
Table 8.5 Opportunities in Europe: Likely Stem Cell Therapy Partners for Device Developers
Table 8.6 Opportunities in Europe: Less Likely Stem Cell Therapy Partners for Device Developers
Table 8.7 Opportunities in Asia-Pacific and Rest of the World: Most Likely Stem Cell Therapy Partners for Device Developers
Table 8.8 Opportunities in Asia-Pacific and Rest of the World: Likely Stem Cell Therapy Partners for Device Developers
Table 8.9 Opportunities in Asia-Pacific and Rest of the World: Less Likely Stem Cell Therapy Partners for Device Developers
Table 8.10 Opportunities in North America: Most Likely Gene Therapy Partners for Device Developers
Table 8.11 Opportunities in North America: Likely Gene Therapy Partners for Device Developers
Table 8.12 Opportunities in North America: Less Likely Gene Therapy Partners for Device Developers
Table 8.13 Opportunities in Europe: Most Likely Gene Therapy Partners for Device Developers
Table 8.14 Opportunities in Europe: Likely Gene Therapy Partners for Device Developers
Table 8.15 Opportunities in Europe: Less Likely Gene Therapy Partners for Device Developers
Table 8.16 Opportunities in Asia-Pacific and Rest of the World: Most Likely Gene Therapy Partners for Device Developers
Table 8.17 Opportunities in Asia-Pacific and Rest of the World: Likely Gene Therapy Partners for Device Developers
Table 8.18 Opportunities in Asia-Pacific and Rest of the World: Less Likely Gene Therapy Partners for Device Developers
Table 10.1 Targeted Drug Delivery Devices Market for Biologics: Key Takeaways
Table 11.1 Seraxis: Key Highlights
Table 11.2 Defymed: Key Highlights
Table 11.3 University of Texas at San Antonio: Key Highlights
Table 11.4 Massachusetts Institute of Technology: Key Highlights
Table 12.1 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device
Table 12.2 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development
Table 12.3 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Status of Development
Table 12.4 Targeted Drug Delivery Devices for Biologics: Distribution by Target Organ
Table 12.5 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Target Organ
Table 12.6 Targeted Drug Delivery Devices for Biologics: Distribution by Target Indication
Table 12.7 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area
Table 12.8 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area and Status of Development
Table 12.9 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Biologic Delivered
Table 12.10 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Therapy Delivered
Table 12.11 Targeted Drug Delivery Devices for Biologics: Distribution by Route of Administration
Table 12.12 Targeted Drug Delivery Device Developers: Distribution by Type of Stakeholder
Table 12.13 Targeted Drug Delivery Device Developers: Distribution by Year of Establishment
Table 12.14 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Company Size
Table 12.15 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Location of Headquarters
Table 12.16 Targeted Drug Delivery Device Developers (Non-Industry Players): Distribution by Location of Headquarters
Table 12.17 Stem Cell Therapies for Neurological Disorders, Publication Analysis: Cumulative Trend by Year, 2015-2020
Table 12.18 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.19 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.20 Gene Therapies for Neurological Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Table 12.21 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.22 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.23 Stem Cell Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Table 12.24 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.25 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.26 Gene Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Table 12.27 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.28 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.29 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.30 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Phase
Table 12.31 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status
Table 12.32 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 12.33 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Therapy
Table 12.34 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.35 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Indication
Table 12.36 Stem Cell and Gene Therapy Clinical Trials: Distribution by Route of Administration
Table 12.37 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.38 Most Active Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Table 12.39 Stem Cell and Gene Therapy: Most Active Non-Industry Players by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Table 12.40 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location
Table 12.41 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.42 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.43 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.44 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.45 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.46 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Table 12.47 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.48 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 12.49 Stem Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.50 Stem Cell Therapy Clinical Trials: Distribution by Trial Phase
Table 12.51 Stem Cell Therapy Clinical Trials: Distribution by Trial Status
Table 12.52 Stem Cell Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 12.53 Stem Cell Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.54 Stem Cell Therapy Clinical Trials: Distribution by Route of Administration
Table 12.55 Stem Cell Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.56 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location
Table 12.57 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.58 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.59 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.60 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.61 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.62 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Table 12.63 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.64 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 12.65 Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.66 Gene Therapy Clinical Trials: Distribution by Trial Phase
Table 12.67 Gene Therapy Clinical Trials: Distribution by Trial Status
Table 12.68 Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 12.69 Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.70 Gene Therapy Clinical Trials: Distribution by Route of Administration
Table 12.71 Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.72 Gene Therapy Clinical Trials: Distribution by Geographical Location
Table 12.73 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.74 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.75 Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.76 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.77 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.78 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Table 12.79 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.80 Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 12.81 Likely Partner Analysis: Distribution of Stem Cell Therapy Developers by Geography
Table 12.82 Likely Partner Analysis: Distribution of Gene Therapy Developers by Geography
Table 12.83 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030 (USD Million)
Table 12.84 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030: Distribution by Type of Device (USD Million)
Table 12.85 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030: Distribution by Target Organ (USD Million)
Table 12.86 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030: Distribution by Target Indication (USD Million)
Table 12.87 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030: Distribution by Target Therapeutic Area (USD Million)
Table 12.88 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030: Distribution by Key Geographical Regions (USD Million)
Table 12.89 Targeted Drug Delivery Devices Market for Biologics in North America, Conservative, Base and Optimistic Scenarios, 2022-2030 (USD Million)
Table 12.90 Targeted Drug Delivery Devices Market for Biologics in Europe, Conservative, Base and Optimistic Scenarios, 2022-2030 (USD Million)
Table 12.91 Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2030 (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 4D Molecular Therapeutics
  2. AbbVie
  3. Abeona Therapeutics 
  4. Advanced Materials and BioEngineering Research
  5. Advantagene
  6. Advaxis
  7. Adverum Biotechnologies
  8. Alcyone Lifesciences
  9. Allergan
  10. AlphaVax
  11. Altaco XXI
  12. American Gene Technologies International
  13. Amgen
  14. Amicus Therapeutics
  15. Anaeropharma Science
  16. Anchiano Therapeutics
  17. AnGes
  18. Angionetics
  19. apceth Biopharma
  20. Apic Bio
  21. Applied Genetic Technologies Corporation
  22. AskBio
  23. Astellas Pharma
  24. Athersys
  25. Atrium Medical
  26. Austrianova
  27. AveXis
  28. Axis Biotec Brasil
  29. Axovant
  30. Azidus Brasil
  31. BHI Therapeutic Sciences
  32. BioCardia
  33. Biogen
  34. BioGenCell
  35. BioInvent
  36. Bioquark
  37. BioRestorative Therapies
  38. Biosense Webster
  39. bluebird bio
  40. Boehringer Ingelheim
  41. Bone Therapeutics
  42. Boston Scientific
  43. Boston TransTec
  44. BrainStorm Cell Therapeutics
  45. Bristol-Myers Squibb
  46. Bukwang Pharmaceutical
  47. Caladrius Biosciences
  48. California Institute for Regenerative Medicine 
  49. Capricor Therapeutics
  50. CAR-T (Shanghai) Biotechnology 
  51. Celixir
  52. CellProthera
  53. Celsion
  54. Celyad
  55. Cesca Therapeutics
  56. CHA Biotech
  57. Children's Hospital of Chongqing Medical University
  58. Chonbuk National University
  59. ClearPoint Neuro
  60. Cold Genesys
  61. CombiGene
  62. Cook Regentec
  63. Copernicus Therapeutics
  64. Corestem
  65. Cornell University
  66. CRISPR Therapeutics
  67. Cynvec
  68. Cytopeutics
  69. Daegu Gyeongbuk Institute of Science & Technology
  70. Defymed
  71. DiscGenics
  72. DNAlite Therapeutics
  73. DNAtrix
  74. Duke University
  75. EdiGene
  76. Editas Medicine
  77. Endsulin
  78. Epeius Biotechnologies
  79. Ever Supreme Bio Technology
  80. Eyevensys
  81. Ferrer Internacional
  82. FKD Therapies
  83. Gemini Therapeutics
  84. Genelux
  85. Genenta Science
  86. Genentech
  87. Generation Bio
  88. Genexine
  89. Genprex
  90. GenSight Biologics
  91. Global Cell Med
  92. Gloriana Therapeutics
  93. Gradalis
  94. Gwo Xi Stem Cell
  95. Gyroscope Therapeutics
  96. Harvard University
  97. Hebei Newtherapy BIo-Pharma Technology
  98. Hemera Biosciences
  99. Hemostemix
  100. Hitachi Chemical
  101. Homology Medicines
  102. Hope Biosciences
  103. HORAMA
  104. Houston Methodist Research Institute
  105. Inovio Pharmaceuticals
  106. Institute of Robotic and Intelligent Systems
  107. IVERIC bio
  108. Janssen
  109. Japan Regenerative Medicine
  110. Japan Tissue Engineering
  111. jCyte
  112. Jennerex Biotherapeutics
  113. Juventas Therapeutics
  114. Kadimastem
  115. Karolinska Institutet
  116. Kolon TissueGene
  117. K-Stem Cell
  118. Kubota Pharmaceutical
  119. Lacerta Therapeutics
  120. Lifecells
  121. Lineage Cell Therapeutics
  122. Living Cell Technologies
  123. Lokon Pharma
  124. Longeveron
  125. Lysogene
  126. Marsala Biotech
  127. Massachusetts Institute of Technology
  128. Med Cell Bahamas
  129. MedImmune
  130. MEDIPOST
  131. MeiraGTx
  132. Mercator MedSystems
  133. Merck
  134. Meridigen Biotech
  135. Mesoblast
  136. Michael J. Fox Foundation
  137. Momotaro-Gene
  138. MultiVir
  139. NanoCor Therapeutics
  140. National Cancer Institute
  141. National University of Ireland, Galway
  142. Nature Cell
  143. Neuracle Genetics
  144. Neuralgene
  145. Neurocrine Biosciences
  146. Neurogene
  147. NeuroGeneration
  148. Neurotech Pharmaceuticals
  149. NextCell Pharma
  150. Nightstar Therapeutics
  151. Nipro
  152. Noray Biosciences Group
  153. Novadip Biosciences 
  154. Novartis
  155. Novo Nordisk
  156. NuVasive
  157. Ocugen
  158. Oncolys BioPharma
  159. Oncos Therapeutics
  160. OncoSec Medical
  161. Orbit Biomedical
  162. ORCA Therapeutics
  163. Oxford BioMedica
  164. Passage Bio
  165. Pattern BioScience
  166. PeriphaGen
  167. Pfizer
  168. PharmaCyte Biotech
  169. Pharmicell
  170. Pluristem Therapeutics
  171. Plus Therapeutics
  172. Prevail Therapeutics
  173. Promethera Biosciences
  174. PsiOxus Therapeutics
  175. PTC Therapeutics
  176. Q Therapeutics
  177. Regeneron Pharmaceuticals
  178. REGENXBIO
  179. Reliance Life Sciences
  180. ReNeuron 
  181. Renishaw
  182. Renova Therapeutics
  183. Riordan Technologies
  184. Roche
  185. ROHTO Pharmaceutical
  186. Royal College of Surgeons in Ireland
  187. SanBio
  188. Sangamo Therapeutics
  189. Sanofi
  190. Sarepta Therapeutics
  191. Scancell
  192. Sclnow Biotechnology 
  193. SCM LifeScience
  194. Seneca Biopharma
  195. Sentien Biotechnologies
  196. Seraxis
  197. Shandong Qilu Stem Cells Engineering
  198. Shanghai East Hospital
  199. Shanghai Sunway Biotech
  200. Shenzhen Hornetcorn Biotechnology
  201. Shire
  202. Sibiono GeneTech
  203. Sigilon Therapeutics
  204. SillaJen
  205. Smartwise
  206. SOTIO
  207. Southwest Research Institute
  208. Spark Therapeutics
  209. Stem Med
  210. Stemedica Cell Technologies
  211. Steminent Biotherapeutics
  212. Stempeutics Research
  213. StrideBio
  214. SWIB Holding
  215. Taiwan Bio Therapeutics
  216. Takeda
  217. Targovax
  218. Taxus Cardium Pharmaceuticals
  219. Tenaya Therapeutics
  220. The Emmes Company
  221. TheraBiologics
  222. Theravectys
  223. Tianhe Stem Cell Biotechnologies
  224. Tianjin Weikai Biological Engineering
  225. TICEBA
  226. Tocagen
  227. Transgene
  228. Translational Research Institute
  229. TransVascular
  230. Trinity College Dublin
  231. U.S. Stem Cell
  232. Ultragenyx Pharmaceutical
  233. uniQure 
  234. United Therapeutics
  235. University of Milan
  236. University of Minnesota Medical School
  237. University of Pennsylvania
  238. University of Texas
  239. VBL Therapeutics
  240. VcanBio Center for Translational Biotechnology
  241. VCN Biosciences
  242. Vericel
  243. Verve Therapeutics
  244. Vessl
  245. ViroMed
  246. Virttu Biologics
  247. Viscofan BioEngineering
  248. Voyager Therapeutics 
  249. XyloCor Therapeutics

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com